GMAB (Genmab A/S) — AI Stock Analysis & Recommendation

Research of September 30, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate GMAB a BUY. The latest price is $36.57.

The research plan

• Entry: $35.67
• Target: $40.74
• Stop: $30.32
• Time horizon: weeks

The setup is a 52-week breakout, suggesting potential for sustained upward momentum over a few weeks.

Why

The setup is a 52-week breakout, suggesting potential for sustained upward momentum over a few weeks. Catalysts to watch: Strong revenue growth (24.9% YoY) and exceptional margins (93.03% gross, 35.24% operating) indicate robust business performance; Overwhelmingly positive analyst consensus with a mean target price of $39.05 suggests significant upside potential; Positive news sentiment driven by raised revenue guidance and strong Q2 earnings provides near-term tailwinds. Key risks: Significant revenue decline expected post-2031 due to Darzalex patent expiration and biosimilar competition; Heavy reliance on Darzalex royalties creates concentration risk, making future growth dependent on pipeline success; Inherent biotechnology sector risks associated with clinical trial failures or regulatory rejections.

What could push GMAB higher

• Strong revenue growth (24.9% YoY) and exceptional margins (93.03% gross, 35.24% operating) indicate robust business performance.
• Overwhelmingly positive analyst consensus with a mean target price of $39.05 suggests significant upside potential.
• Positive news sentiment driven by raised revenue guidance and strong Q2 earnings provides near-term tailwinds.

Key risks for GMAB

• Significant revenue decline expected post-2031 due to Darzalex patent expiration and biosimilar competition.
• Heavy reliance on Darzalex royalties creates concentration risk, making future growth dependent on pipeline success.
• Inherent biotechnology sector risks associated with clinical trial failures or regulatory rejections.

What each AI research team found

Fundamental team: Bullish · valuation: undervalued

Genmab presents a compelling bullish case driven by strong revenue growth, exceptional margins, and a robust pipeline, supported by overwhelmingly positive analyst sentiment. While current earnings growth is negative and debt is elevated, these are manageable within the context of its strong cash flow and the biotech sector's capital structure, making it undervalued at current levels.

• Strong revenue growth (24.9% YoY) driven by successful products and a promising pipeline.
• Exceptional gross margins (93.03%) and operating margins (35.24%) indicate significant pricing power and operational efficiency.
• Analyst consensus is overwhelmingly 'strong_buy' with a mean target price of $39.05, suggesting substantial upside potential.

Technical team: Bullish

GMAB is exhibiting a strong long-term uptrend with recent bullish continuation signals on the daily chart. While current price action shows consolidation near resistance and subdued volume, the overall pattern suggests a potential breakout. A close above the 52-week high with increased volume would confirm bullish momentum.

• Price is consolidating near resistance, with short-term bullish momentum but facing selling pressure, suggesting a neutral outlook with potential for a breakout above $35.67.
• The stock is trading in a tight range with low volume, suggesting a neutral outlook until a clear breakout or breakdown occurs with increased volume.
• The stock is trading near resistance with mixed signals from indicators, suggesting a neutral outlook with potential for a breakout or pullback.

Sentiment team: Bullish

Genmab (GMAB) displays a strong positive sentiment across news, social media, and professional analyst views, driven by robust financial performance, raised guidance, and promising pipeline catalysts. While concerns regarding pipeline risks and the Darzalex patent cliff exist, the overwhelming positive momentum and institutional buying suggest a bullish outlook.

• Genmab (GMAB) exhibits a predominantly positive news sentiment driven by raised revenue guidance, strong Q2 earnings, and promising pipeline developments, though some analyst concerns regarding pipeline risks and patent cliffs persist. (Score: 0.15)
• Genmab (GMAB) exhibits positive retail and analyst sentiment driven by strong financial performance, raised guidance, and promising late-stage pipeline catalysts, though concerns around patent cliffs and valuation persist. (Score: 0.25)
• Genmab (GMAB) exhibits a positive sentiment driven by strong financial results, raised guidance, and significant analyst upgrades, alongside robust institutional buying, though concerns remain regarding pipeline concentration and the Darzalex patent cliff....

Risk team: High

GMAB presents a high-risk profile due to significant concentration risk on Darzalex royalties, inherent biotech pipeline and regulatory uncertainties, and elevated volatility. The stock's history of deep drawdowns and high implied volatility further amplifies downside potential, necessitating a small position size and robust risk management.

• Darzalex Royalty Expiration: Significant revenue decline expected post-2031 due to patent expiration and biosimilar competition for Darzalex, which currently represents a substantial portion of Genmab's revenue.
• Pipeline Concentration: Heavy reliance on Darzalex royalties creates a significant concentration risk; future growth depends heavily on the success of new proprietary pipeline assets to offset declining royalty income.
• Clinical Trial and Regulatory Risk: Biotechnology sector inherent risk of clinical trial failures or regulatory rejection for pipeline candidates, which are critical for future revenue generation.

GMAB at a glance

Market value	$21.0B
Price / earnings	26.3
Revenue growth (year over year)	19.2%
Profit margin	25.9%
Debt / equity	0.90

Every AI call on GMAB since September 28, 2026, and what happened next (3 calls) →

Research of September 30, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.